Mutations in the EGFR and echinoderm microtubule-associated protein 4-mesenchymal lymphoma kinase fusion (EML4-ALK) mutations are more common in NSCLC, so in future research we will analyze the mutation types and subtypes of these two genes and introduce survival analysis of combination therapy and prognosis analysis of targeted therapy. This evidence concerns the gene ALK and non-small cell lung carcinoma.